Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Deglycosylated kringle 1-3 region fragments of plasminogen and methods of use

a plasminogen and region fragment technology, applied in the field of deglycosylated kringle 13 region proteins, can solve the problems of abnormal or undesired angiogenesis, and achieve the effects of modulating angiogenesis, increasing the anti-angiogenic activity of these proteins, and inhibiting unwanted angiogenesis

Inactive Publication Date: 2007-01-02
CHILDRENS MEDICAL CENT CORP
View PDF8 Cites 6 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Benefits of technology

[0013]Compositions and methods are provided herein that are effective for modulating angiogenesis, and inhibiting unwanted angiogenesis, especially angiogenesis related to tumor growth. In particular, the present invention provides deglycosylated kringle 1-3 region proteins that are fragments of plasminogen. It is a surprising discovery of the present invention that deglycosylation of kringle 1-3 region proteins dramatically increases the antiangiogenic activity of these proteins. It is to be understood that the deglycosylated kringle 1-3 region proteins described herein include fusion proteins wherein a deglycosylated kringle 1-3 region protein is contiguous with one or more other proteins. In a preferred embodiment, the fusion protein comprises a deglycosylated kringle 1-3 region protein and another antiangiogenic protein.
[0015]The present invention also includes antibodies specific for the deglycosylated kringle 1-3 region proteins, antibodies that inhibit the binding of antibodies specific for deglycosylated kringle 1-3 region proteins, and antibodies specific for a deglycosylated kringle 1-3 region protein receptor. These antibodies can be polyclonal antibodies or monoclonal antibodies. The antibodies specific for the deglycosylated kringle 1-3 region proteins can be used in diagnostic kits to detect the presence and quantity of deglycosylated kringle 1-3 region proteins which is diagnostic or prognostic for the occurrence or recurrence of cancer or other diseases mediated by angiogenesis. Antibodies specific for deglycosylated kringle 1-3 region proteins may also be administered to a human or animal to passively immunize the human or animal against deglycosylated kringle 1-3 region proteins, thereby reducing angiogenic inhibition.
[0019]It is another object of the present invention to provide compositions and methods for increasing an in vivo concentration of deglycosylated kringle 1-3 region proteins.

Problems solved by technology

However, angiogenesis also occurs under abnormal or undesired conditions such as during tumor development, growth and metastasis.

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Deglycosylated kringle 1-3 region fragments of plasminogen and methods of use
  • Deglycosylated kringle 1-3 region fragments of plasminogen and methods of use
  • Deglycosylated kringle 1-3 region fragments of plasminogen and methods of use

Examples

Experimental program
Comparison scheme
Effect test

example 1

Isolation of Glycosylated and Deglycosylated Kringle 1-3 Region Proteins

[0091]Human plasminogen was purified using affinity chromatography as described in Brockway, W. J. and Castellino, F. J., “Measurement and the binding of antifibrinolytic amino acids to various plasminogens”Arch. Biochem. Biophys. 151:194–199 (1972). One liter of human plasma (Children's Hospital blood bank) was applied to a 200 mL lys-Sepharose 4b (Pharmacia) column at a flow rate of 2–3 ml / minute. The column, previously equilibrated with 50 mM Tris pH 7.4 (Sigma) was then washed with 500 mL 50 mM tris / 1M NaCl pH 7.4. Bound plasminogen was eluted with 200 mL 50 m M tris / 200 mM ε-aminocaproic acid (εACA). The purity of this material was greater than 95% as assessed by SDS-PAGE. Human plasminogen was further fractionated into glycosylated plasminogen (plasminogen 1) and deglycosylated plasminogen (plasminogen 2) using lectin affinity chromatography. Human plasminogen (10 mg) was applied to a 5 mL conA HiTrap colu...

example 2

Deglycosylation of Plasminogen Results in an Increased Yield of Kringle 1-3 Region Proteins

[0094]Equal amounts of plasminogen 1 and plasminogen 2 were digested with PPE, and the kringle 1-3 region proteins purified as described in Example 1 using a combination of affinity chromatography (lys-Sepharose) to purify kringle 1-3 region proteins and other lysine binding fragments of plasminogen, and gel filtration (Superdex200) to separate kringle 1-3 region proteins from kringle 4. FIG. 2 shows a typical chromatogram from the affinity column, demonstrating the reduced yield obtained when plasminogen 1 is used, as a substrate compared to plasminogen 2. FIG. 3 shows the chromatogram obtained from a typical gel filtration experiment as described in Example 1). It was noted that kringle 1-3 region protein from plasminogen I has a slightly lower retention time (13.77 minutes) than deglycosylated kringle 1-3 region protein (14.36 minutes), as would be expected from this glycosylated fragment. ...

example 3

Deglycosylated Kringle 1-3 Region Proteins Have Increased Antiangiogenic Activity as Compared to Glycosylated Kringle 1-3 Region Proteins

[0097]Both kringle 1-3 region protein glycoforms were assayed for their ability to inhibit the proliferation of bovine endothelial cells as described in Example 1. Both kringle 1-3 region protein glycoforms inhibited endothelial cell proliferation. However, glycosylated kringle 1-3 region protein, which contains an N-linked carbohydrate, has a measured IC50 value of approximately 13 μg / mL, whereas deglycosylated kringle 1-3 region protein, the glycoform, lacking an N-linked carbohydrate, has a measured IC50 value of approximately 2.4 μg / nL. Thus, deglycosylated kringle 1-3 region protein appears to be a much more efficient inhibitor of endothelial cell proliferation, and in particular was 4–5 fold more efficient as an inhibitor of endothelial cell proliferation.

[0098]All patents, publications and abstracts cited above are hereby incorporated by ref...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

PropertyMeasurementUnit
pHaaaaaaaaaa
volumeaaaaaaaaaa
volumeaaaaaaaaaa
Login to View More

Abstract

Disclosed are deglycosylated fragments of a kringle 1-3 region of plasminogen, nucleotides encoding deglycosylated kringle 1-3 region proteins and antibodies specific for deglycosylated kringle 1-3 region proteins. The compositions of the present invention have increased antiangiogenic activity as compared to previously isolated kringle 1-3 region proteins. Also included in the present invention are methods of treating angiogenesis-associated diseases and conditions such as cancer using the compositions described herein.

Description

CROSS REFERENCE TO RELATED APPLICATIONS[0001]This application claims priority to U.S. Provisional Patent Application Ser. No. 60 / 119,562, filed Feb. 10, 1999 and U.S. Provisional Patent Application Ser. No. 60 / 128,062, filed Apr. 7, 1999.[0002]This invention was made with government support under Grant No.(s) CA 45548 by the NIH. The government may have certain rights in the invention.FIELD OF THE INVENTION[0003]The present invention relates to compositions and methods for the modulation of angiogenesis. More particularly, the present invention relates to deglycosylated kringle 1-3 region proteins that are useful for the treatment of angiogenesis-associated diseases such as cancer.BACKGROUND OF THE INVENTION[0004]As used herein, the term “angiogenesis” means the generation of new blood vessels into a tissue or organ. Under normal physiological conditions, humans or animals undergo angiogenesis only in very specific restricted situations. For example, angiogenesis is normally observe...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Patents(United States)
IPC IPC(8): C07K1/00A01N61/00A61K35/14A61K38/16C07K14/00C07K16/00C07K17/00C07H21/02
CPCA61K38/16C12Y304/21007C12N9/6435
Inventor PIRIE-SHEPHERD, STEVENFOLKMAN, M. JUDAHSIM, KIM LEEMACDONALD, NICHOLASLIANG, HONG
Owner CHILDRENS MEDICAL CENT CORP
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com